STOCK TITAN
  1. Home
  2. News
  3. KNW

Know Labs Inc - KNW STOCK NEWS

Welcome to our dedicated news page for Know Labs (Ticker: KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Know Labs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Know Labs's position in the market.

News
Know Labs to Present Clinical Research at the 2024 American Physiology Summit
Rhea-AI Summary
Know Labs, Inc. (KNW) has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit, showcasing significant progress in non-invasive blood glucose monitoring technology. The company's proprietary radiofrequency (RF) dielectric sensor has shown improved accuracy in measuring blood glucose, with recent clinical studies demonstrating stability, repeatability, and accuracy of its non-invasive continuous blood glucose monitor. Know Labs aims for FDA clearance and plans to deploy its wearable CGM in large-scale clinical trials to determine real-world applicability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
conferences clinical trial
-
News
Know Labs’ Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study
Rhea-AI Summary
Know Labs, Inc. (KNW) announces positive interim results from its clinical research study on non-invasive blood glucose monitoring in participants with diabetes. The study demonstrates a Mean Absolute Relative Difference (MARD) of 11.1% using the company's proprietary RF sensor, showing promise for future FDA-cleared continuous glucose monitoring devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.39%
Tags
clinical trial
-
News
Know Labs Secures U.S. $12 Million Funding for Company’s Further Execution on Its Clinical Research and Development Initiatives
Rhea-AI Summary
Know Labs, Inc. (KNW) secures a funding agreement for up to $12 million with Lind Global Fund II LP, enabling accelerated development of non-invasive medical diagnostic technology. The investment will support hardware development, expanded data collection, algorithm development, and intellectual property expansion. The company aims to validate its technology in large-scale clinical trials for a non-invasive continuous glucose monitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.72%
Tags
clinical trial
News
Know Labs Announces the KnowU™, its Wearable Non-Invasive Continuous Glucose Monitor
Rhea-AI Summary
Know Labs, Inc. announces the KnowU, a wearable non-invasive continuous glucose monitor, incorporating a proprietary sensor for FDA submission. The device is smaller, lighter, and includes machine learning capabilities, aiming to revolutionize diabetes management. The KnowU supports accelerated data collection for FDA clinical trials, offering a future solution for accessible and accurate diabetes care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
-
News
Know Labs, Inc. Reports First Quarter FY2024 Results
Rhea-AI Summary
Know Labs, Inc. (KNW) reported financial results for Q1 FY 2024, showing a 9.8% reduction in net loss, with a net loss of $3.45 million. Earnings Per Share improved by 50% to a loss of $0.04. The company had cash and cash equivalents of $4.82 million as of December 31, 2023. Know Labs aims to raise funds through equity, preferred stock, and convertible debentures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.91%
Tags
earnings
-
News
Know Labs, Inc. to Host Review of First Quarter Fiscal Year 2024 Results on February 14, 2024
Rhea-AI Summary
Know Labs, Inc. (KNW) will host a webcast to review business updates and first quarter results for fiscal year 2024 on February 14, 2024. The company is an emerging developer of non-invasive medical diagnostic technology and is focused on developing the first FDA-cleared non-invasive blood glucose monitoring device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
conferences earnings
News
Know Labs to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
Rhea-AI Summary
Know Labs, Inc. (KNW) will present updated clinical research results and developments of its non-invasive blood glucose monitor at the International Fair of New Technologies in Diabetes. The company will share updates on the latest developments of its non-invasive blood glucose monitor and present results from its ongoing clinical research, with two abstracts accepted for e-poster presentation in the scientific program. Dr. Virend K. Somers of the Mayo Clinic will present the results from the current clinical research protocol, assessing the accuracy of the Know Labs radiofrequency (RF) sensor for non-invasive blood glucose measurement in participants with prediabetes and Type 2 diabetes using venous blood as comparative reference. Know Labs will also sponsor an invitation-only luncheon hosted by Children With Diabetes (CWD) during the conference to discuss non-invasive glucose monitoring innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
none
-
News
Know Labs, Inc. Reports Fourth Quarter and Fiscal Year 2023 Results
Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) reported a net loss of $15.29 million dollars in FY2023, compared to a net loss of $20.07 million dollars in FY2022, a reduction in net loss of 23.8%. R&D expenses for FY2023 were $7.73 million dollars, an increase of 43.5% year over year. The company had cash and cash equivalents of $8.02 million dollars, and it expects to raise additional funds through the issuance of equity, preferred stock, and convertible debentures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.33%
Tags
earnings
-
News
Know Labs Expands Medical and Scientific Advisory Board
Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) appoints four new members to its Medical and Scientific Advisory Board. Jeff Hitchcock, Karmeen Kulkarni, Dr. Meng Tan, and Dr. Satish Garg bring extensive clinical diabetes management and FDA expertise to the board. They will support the development and FDA clearance of the company's non-invasive continuous glucose monitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.76%
Tags
management
News
Know Labs, Inc. to Host Review of Fiscal Year 2023 Results on December 19, 2023
Rhea-AI Summary
Know Labs, Inc. (NYSE American: KNW) will host a webcast to review business updates and results for its fiscal year ended on September 30, 2023, on December 19, 2023, beginning at 1:30 pm PT. The company is an emerging developer of non-invasive medical diagnostic technology and is progressing in developing the first FDA-cleared non-invasive blood glucose monitoring device.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
conferences earnings
Stock KNW logo
Know Labs Inc

NYSE:KNW

KNW Rankings

#4673 Ranked by Market Cap
#5357 Ranked by Stock Gains
N/A Ranked by Dividends

KNW Stock Data

54.05M
56.53M
26.81%
2.98%
0.46%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Link
US
Seattle

About KNW

visualant is a public company whose shares trade under the stock symbol, vsul. the visualant spectral pattern matching™ technology directs structured light onto a substance, through a liquid/gas, or off a surface, to capture a unique chromaid™. when matched against existing databases, a chromaid can be used to identify, detect, or diagnosis markers invisible to the human eye. chromaid scanhead modules can be integrated into a variety of mobile or fixed-mount form factors. the patented technology is disruptive, making it possible to effectively conduct analyses in the field that could only previously be performed by large and expensive lab–based tests.